The FDA’s nod extends Benlysta’s indication in the US, making it the first approved treatment for pediatric lupus nephritis. Benlysta was also the first approved targeted therapy for lupus nephritis in adults in 2011.
https://www.pharmalive.com/wp-content/uploads/2021/11/U.S.-secures-GSK-Vir-COVID-19-antibody-therapy-doses-worth-1-bln-Reuters-11-17-21.jpg503960BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-07-28 08:33:142022-07-28 08:34:13GSK’s Benlysta Becomes First Biologic Approved for Lupus Nephritis in Kids
